Clin2
NCT07330778Likely a fitRecruiting

Study of CDX-622 for mild to moderate asthma

Mild to Moderate Asthma

Part of Immune system & allergy, Lungs & breathing clinical trials.

This trial is testing an investigational drug called CDX-622 for people with mild to moderate asthma. The study aims to see if it can help control asthma symptoms and improve lung function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
12 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You must have been diagnosed with mild to moderate asthma for at least 12 months.
  • Your lung function (FEV1) must be at least 70% of what is expected for someone your age and size.
  • Your asthma must be reversible, meaning your breathing improves by at least 12% and 200mL after using a rescue inhaler.
  • If you are able to become pregnant or father a child, you must agree to use contraception during the study and for 150 days after treatment.
  • You cannot have used certain biologic medications (like tezepelumab or briquilimab) in the past.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07323654Recruiting· Phase 2
Oral KT-621 for moderate to severe eosinophilic asthma

This trial tests an oral medication called KT-621 for people with moderate to severe eosinophilic asthma. It aims to see if the drug can help control asthma better than the standard inhaled treatments alone.

Lancaster, California
NCT07025200Recruiting
Severe asthma study using bronchoscopy to check treatment

This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.

Vienna, State of Vienna
NCT07746687Not yet recruiting· Phase 2
Study of a new drug for moderate to severe asthma

This study tests an investigational drug to see if it can improve asthma control in people whose asthma is not well managed with current treatments. It may help reduce symptoms and improve lung function.

NCT07403487Not yet recruiting· Phase 2
Testing an injectable medicine for asthma

This study tests a new injected medicine (RC1416) for people with moderate-to-severe asthma that is not well controlled with daily inhalers. It may help reduce asthma attacks and improve breathing.

Suzhou, Anhui
NCT07372287Recruiting· Phase 3
Study of CM326 for moderate to severe asthma

This trial tests an investigational drug called CM326 for people with moderate to severe asthma that is not well controlled with current treatments. It aims to see if CM326 can help reduce asthma attacks and improve breathing.

Shanghai, Shanghai Municipality
NCT06488755Recruiting· Phase 3
Study of an asthma treatment for people with moderate to severe asthma

This trial tests an experimental medication called SIM0718 to see if it can improve asthma control and reduce flare-ups. It may be an option for people whose asthma is not well-controlled with their current inhaler therapy.

Beijing, Beijing Municipality

Hear when a new Mild to Moderate Asthma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.